Form 8-K ANAPTYSBIO, INC For: Jun 03
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Stifel Reiterates Buy Rating on AnaptysBio (ANAB)
June 4, 2025 7:15 AM EDTStifel analyst Alex Thompson reiterated a Buy rating and $55.00 price target on AnaptysBio (NASDAQ: ANAB).
The analyst comments "ANAB reported full 28wk results from the Rosnilimab Ph2b Rheumatoid Arthritis (RA) study. Rosnilimab continues to look highlyactive with efficacy competitive... More
